0.3072 0.019 (6.74%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.8 | 1-year : | 1.12 |
Resists | First : | 0.68 | Second : | 0.95 |
Pivot price | 0.34 ![]() |
|||
Supports | First : | 0.25 | Second : | 0.2 |
MAs | MA(5) : | 0.28 ![]() |
MA(20) : | 0.39 ![]() |
MA(100) : | 0.63 ![]() |
MA(250) : | 1.4 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 13.8 ![]() |
D(3) : | 7.4 ![]() |
RSI | RSI(14): 42.6 ![]() |
|||
52-week | High : | 2.63 | Low : | 0.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ERNA ] has closed above bottom band by 33.2%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.32 - 0.33 | 0.33 - 0.33 |
Low: | 0.28 - 0.28 | 0.28 - 0.28 |
Close: | 0.3 - 0.31 | 0.31 - 0.31 |
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Wed, 15 Jan 2025
ERNA-101 extends survival in mice with ovarian cancer - BioWorld Online
Tue, 14 Jan 2025
Eterna's ERNA-101 Shows Breakthrough Results in Ovarian Cancer Treatment Study - StockTitan
Tue, 14 Jan 2025
Eterna Therapeutics Reports Positive Preclinical Results For ERNA-101 In Ovarian Cancer - Nasdaq
Mon, 13 Jan 2025
Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com
Fri, 10 Jan 2025
Eterna Therapeutics Faces Nasdaq Compliance and Board Changes - TipRanks
Mon, 06 Jan 2025
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 51 (M) |
Held by Insiders | 3.28e+006 (%) |
Held by Institutions | 336.3 (%) |
Shares Short | 54 (K) |
Shares Short P.Month | 0 (K) |
EPS | -2.186e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -10 % |
Return on Assets (ttm) | 491.4 % |
Return on Equity (ttm) | -29.5 % |
Qtrly Rev. Growth | 162000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -23166 |
Qtrly Earnings Growth | -8.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -16 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 5.82 |
Dividend | 0 |
Forward Dividend | 44460 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |